

Special Issue

Epigenetics in Endocrine-Related Cancer

Message from the Guest Editor

Endocrine-related cancers are a group of solid tumors that arise within endocrine glands such as thyroid, ovary and prostate. Current treatments target hormones that support tumor growth, but hormone-targeted therapies often lead to endocrine resistance and aggressive tumors. Treatment resistance and identification of new therapeutic avenues are critical for offering cancer patients a longer life and better quality of life.

This Special Issue on 'Epigenetics in Endocrine-Related Cancer' aims to highlight how changes in epigenetic marks can be utilized as biomarkers for patient stratification, further understanding the role epigenetics plays in treatment resistance in endocrine-related cancers and identifying epigenetic modifiers as novel therapeutic targets, all towards utilizing the epigenetic landscape in precision medicine.

Guest Editor

Dr. Jennie N Jeyapalan

School of Veterinary Medicine and Science, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham NG7 2RD, UK

Deadline for manuscript submissions

closed (25 December 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/216462

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)